Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2022; filed May 16, 2022. The supplied metadata says “2021 Q3,” but the filing itself reports the period ended March 31, 2022. Financial statements are unaudited.
Business context
Propanc is a development-stage biotechnology company focused on cancer treatments. Its lead candidate, PRP, is a preclinical pro-enzyme formulation; the company had no product revenue. Management described plans for a first-in-human study in advanced solid tumors, subject to development progress and financing.
Financial results and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $0 in 2022 and 2021 | $0 in 2022 and 2021 |
| Operating expenses | $502,181; prior year $427,952 | $1,391,678; prior year $1,085,207 |
| Net loss | $462,687; prior year $417,738 | $1,753,322; prior year $1,246,926 |
| Net loss available to common stockholders | $700,076; prior year $417,738 | $2,198,953; prior year $1,246,926 |
| Net cash used in operating activities | $1,025,306 for nine months; prior year $908,977 |
At March 31, 2022, cash was $133,885, current assets were $144,506, current liabilities were $3,116,880, and total liabilities were $3,116,880. Working capital deficit was $2,972,374; stockholders’ deficit was $2,947,420. Net convertible notes and related accrued interest were $1,075,702, and embedded conversion-option liabilities were $56,612. No revenue means operating margins are not meaningful.
For the nine months, financing provided $1,116,500: $641,500 net proceeds from convertible notes and $475,000 from warrant exercises. Cash increased from $2,255 at June 30, 2021 to $133,885. The company reported no cash paid for income taxes and $1,485 paid for interest.
Changes, financing, and unusual items
- Nine-month net loss increased by about $506,000 year over year. Administration expense rose $308,409, while R&D expense was broadly similar ($147,702 versus $145,898). Interest expense increased to $455,133 from $420,017.
- Common shares issued and outstanding rose from 14,055,393 at June 30, 2021 to 85,030,026 at March 31, 2022. The filing also reports 122,193,541 shares issued and outstanding as of May 16, 2022. Share issuances included debt conversions, services, and warrant exercises.
- Debt financing includes variable-price convertible notes with conversion discounts, default provisions, and put premiums. Put-premium accretion was $380,962 for the nine months; $227,150 was reclassified to additional paid-in capital after conversions. A $445,631 deemed dividend from alternate cashless warrant exercises increased the loss attributable to common stockholders, but not reported net loss.
- The company entered a $5 million equity-line agreement with Dutchess Capital, subject to conditions including an effective resale registration statement. Subsequent to quarter-end, it reported a $66,106 drawdown and issuance of 4,242,998 shares on April 5, 2022.
Outlook, risks, and contingencies
- Going concern: Management said the losses, operating cash use, and working-capital and stockholders’ deficits raise substantial doubt about the company’s ability to continue as a going concern for at least 12 months from the report date. It said available cash and current commitments were insufficient to meet obligations over the next 12 months; additional financing is necessary, with no assurance it will be available on acceptable terms.
- Development and outlook: The filing provides no quantified revenue or earnings guidance. It reports a March 2022 U.S. patent notice of allowance concerning cancer stem-cell treatment methods and a May 2022 purchase of pharma-grade raw materials for planned PRP clinical development. Clinical timing and progress remain dependent on financing and development outcomes.
- Defaults and other obligations: The company disclosed defaults on notes issued in 2017 and 2019 for $145,280 of principal and $38,074 of accrued interest at March 31, 2022, and said it was discussing maturity extensions. Certain notes have past-due maturities and default interest or penalty terms. A $30,000 IRS penalty, plus accrued interest, remains accrued while the company awaits an IRS response.
- Controls: Management concluded disclosure controls were not effective at March 31, 2022. Disclosed material weaknesses include lack of written control documentation, insufficient segregation of duties, no audit committee, and insufficient financial-reporting review and U.S. GAAP expertise. Planned remediation is subject to raising capital.
- COVID-19 effects on operations, financing, and results remain uncertain. The company reported no material pending litigation. It has 39 granted patents and 26 under examination, according to the filing.
Key facts for investors to verify
- Confirm the reporting period: the filing is for the quarter ended March 31, 2022, despite the “2021 Q3” request metadata.
- Review subsequent cash, debt maturities, defaults, and financing availability; the company disclosed substantial doubt about going concern and a need for additional capital.
- Track share counts and potential dilution from discounted convertible notes, warrant features, reserved shares, and the equity line.
- Verify progress and funding for PRP’s planned clinical development, including any regulatory filings, study initiation, and patent status.
- Assess whether the disclosed material weaknesses have been remediated and whether financial reporting controls improve.